Treatment of refractory temporal arteritis with adalimumab

Ahmed, M. M.; Mubashir, E.; Hayat, Samina; Fowler, Marjorie; Berney, S.M.

doi:10.1007/s10067-006-0375-2

Cited by 50 publications

(22 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Classical disease therapy relies on a high dose of GC administration once the clinical finding is suggestive of the disease [25,26]. Relapse is common in 60-70% of patients thus, other therapeutic modalities are required [23,27,28]. A meta-analysis in 2014 [29], included five studies about anti TNF alpha agents in GCA.…”

Section: Giant Cell Arteritismentioning

confidence: 99%

Use of Anti TNF-α Therapy in Systemic Vasculitis

Almteri¹,

Alshaiki²,

Hafiz³

et al. 2017

J Vasc

View full text Add to dashboard Cite

There are several vascultic disorders still labeled as difficult-to-treat cases. Effective treatment for those patients is warranted to reduce the mortality and morbidity that resulting from these disorders. An extensive review for the literatures that addressed using of ant TNF-alpha in several vascultic disorders was conducted. Use of anti TNFalpha agents is a promising modality in several vascultic disorders. Despite lacking well-conducted randomized controlled trials, more open-label studies are required to examine in-depth the safety and efficacy of those agents.

show abstract

Section: Giant Cell Arteritismentioning

confidence: 99%

Use of Anti TNF-α Therapy in Systemic Vasculitis

Almteri¹,

Alshaiki²,

Hafiz³

et al. 2017

J Vasc

View full text Add to dashboard Cite

show abstract

“…Ингибиторы фактора некроза опухоли аль-фа (ФНО-α) эффективны при большом количестве воспалительных процессов, в том числе при рев-матоидном артрите и анкилозирующем спонди-лите [27]. В настоящее время отсутствуют доказа-тельства того, что применение анти-ФНО-терапии имеет преимущество в лечении ГКА, несмотря на отдельные сообщения об успешном исполь-зовании этой группы лекарственных средств [4].…”

Section: ингибиторы фактора некроза опухоли альфаunclassified

Giant cell arteritis. Part II

Makarenko¹

2017

Vestnik VSMU

View full text Add to dashboard Cite

Vestnik VGMU. 2017;16(5):31-39. Резюме.Основу терапии гигантоклеточного артериита составляют глюкокортикостероиды. Для уменьшения риска ослож-нений, ассоциированных с их применением, может быть использована иммуносупрессивная терапия метотрекса-том. В 2016 г. опубликованы рекомендации по ведению пациентов с гигантоклеточным артериитом, созданные Французской исследовательской группой по изучению васкулитов крупных сосудов (Groupe d'Étude Frances ais des Artérites des grosvaisseaux, GEFA). Они касаются номенклатуры заболевания, классификационных критериев гигантоклеточного артериита, роли биопсии височной артерии и методов визуализации в диагностике этой пато-логии, способов выявления поражений аорты и ее ветвей, режима назначения глюкокортикостероидов, лечения осложнений гигантоклеточного артериита, показания к применению иммунодепрессантов или таргетной биоло-гической терапии, а также ведения пациентов с обострениями и рецидивами. Ключевые слова: гигантоклеточный артериит, височный артериит, лечение, рекомендации. Abstract.The basis for the therapy of giant cell arteritis is glucocorticosteroids. To reduce the risk of complications associated with their use, immunosuppressive therapy with methotrexate may be used. In 2016 recommendations for the management of patients with giant cell arteritis, elaborated by the French Research Group for the Study of Vasculitis of Large Vessels (Groupe d'Étude Frances ais des Artérites des grosvaisseaux, GEFA), were published. They concern the nomenclature of the disease, the classification criteria of giant cell arteritis, the role of temporal artery biopsy and imaging methods in the diagnosis of this pathology, the methods used for detecting aorta and its branches lesions, the mode of glucocorticosteroids administration, the treatment of giant cell arteritis complications, indications for the use of immunosuppressants or targeted biotherapy as well as the management of patients with exacerbations and relapses.

show abstract

“…TNF has been demonstrated in up to 60% of the cells in all areas of inflamed arteries (297), and inhibition of this cytokine may be an attractive therapeutic option in GCA. Early case reports (298,299,300,301,302,303,304,305) of favorable response to TNF inhibitors indicated that biological therapy could be an alternative to CS or at least be used in patients failing to respond to CS. However, suggestions of efficacy of TNF inhibitors have not withstood further drug trials.…”

Section: Alternative Treatment Strategiesmentioning

confidence: 99%

Diagnosis and Treatment of Giant Cell Arteritis (Temporal Arteritis) – Past, Current and Future Aspects

Gran¹

2011

Advances in the Diagnosis and Treatment of Vasculitis

View full text Add to dashboard Cite

Treatment of refractory temporal arteritis with adalimumab

Cited by 50 publications

References 10 publications

Use of Anti TNF-α Therapy in Systemic Vasculitis

Use of Anti TNF-α Therapy in Systemic Vasculitis

Giant cell arteritis. Part II

Diagnosis and Treatment of Giant Cell Arteritis (Temporal Arteritis) – Past, Current and Future Aspects

Contact Info

Product

Resources

About